ReviewOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2026
Contemporary Management of Malignancies of the Parotid Gland: A State-of-the-Art Review.
Review in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesTo provide a systematic update on the contemporary management of malignancies of the parotid gland (MPG), focusing on evidence-based practices and emerging therapeutics. DATA SOURCES: PubMed literature search. REVIEW
methodsA search protocol was designed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) process for articles published between August 1, 2019, and August 1, 2024. Primary exclusion criteria were non-English text, abstracts, and case reports/series. Secondary inclusion criteria were articles specific to MPG diagnosis, histology, outcomes, and management, including surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy.
conclusionA total of 1614 articles were identified, and 137 articles were included in the final review. Most studies on low-grade MPG found that surgery alone was noninferior to surgery and adjuvant radiotherapy for local control. Elective neck dissection provided survival benefits for high-grade, but not low-grade, MPG. Most MPG are chemotherapy-resistant. Adjuvant chemotherapy provides limited survival benefits while significantly worsening quality of life and, thus, should be used only in select patients. Immunotherapy and targeted therapies for markers, including HER-2, TRK, and androgen receptors, have shown promising results in the treatment of advanced MPG. IMPLICATIONS FOR PRACTICE: Advances in the treatment of MPG have improved survival while minimizing treatment toxicity and improving quality of life. Future studies are needed to emphasize personalized oncologic treatment for patients with these rare malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.